keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia, statins,

keyword
https://www.readbyqxmd.com/read/27903988/metabolic-syndrome-in-relation-to-risk-of-meningioma
#1
Corinna Seliger, Christoph R Meier, Claudia Becker, Susan S Jick, Martin Proescholdt, Ulrich Bogdahn, Peter Hau, Michael F Leitzmann
BACKGROUND: Meningioma is a frequent primary intracranial tumor, the etiology of which is potentially related to adiposity. Metabolic syndrome (MetS) is an increasingly common disease characterized by having at least three of the following conditions: central adiposity, arterial hypertension, dyslipidemia, and insulin resistance. Only one prior study investigated MetS in relation to meningioma risk and found a positive association between the two. RESULTS: Among 2,027 cases and 20,269 controls, body mass index was positively associated with meningioma (p-value for trend < 0...
November 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/27885915/effect-of-an-snp-in-scap-gene-on-lipid-lowering-response-to-rosuvastatin-in-indian-patients-with-metabolic-syndrome
#2
Misbahuddin M Rafeeq, Farida Ahmad, Syed Z Rahman, Sheelu S Siddiqi, Shazi Shakeel
AIM: Statins treat dyslipidemia associated with metabolic syndrome. Genetic factors contribute to variable response. Sterol regulatory element-binding factors cleavage-activating protein (SCAP) pathway regulates lipid homeostasis, so effect of SNP in SCAP gene on rosuvastatin response was studied. MATERIALS & METHODS: Metabolic syndrome patients with low-density lipoprotein-cholesterol ≥130 mg/dl, were prescribed rosuvastatin 5 mg for 3 months. Lipids were measured initially and finally, and genotyping done...
November 25, 2016: Pharmacogenomics
https://www.readbyqxmd.com/read/27877092/pediatric-statin-administration-navigating-a-frontier-with-limited-data
#3
REVIEW
Jonathan Wagner, Susan M Abdel-Rahman
Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients' specific needs...
September 2016: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/27876130/the-potential-behavioral-and-economic-impacts-of-widespread-hmg-coa-reductase-inhibitor-statin-use
#4
Mathew H Gendle
Dyslipidemia is a common pathology throughout the industrialized world, and HMG-CoA reductase inhibitors (statins) are often administered to treat elevated lipid levels. Substantial concern has been raised regarding the aggressive clinical lowering of cholesterol, particularly in light of a growing body of research linking low circulating lipid levels with negative behavioral outcomes in both human samples and non-human primate models. In 2009, Goldstein and colleagues tentatively speculated that the greed, impulsiveness, and lack of foresight that lead to the worldwide economic collapse in 2007-2008 could have been caused (in part) by depressed population cholesterol levels resulting from the widespread use of statins by workers in the financial services industry...
December 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/27868450/pharmacological-management-of-diabetic-dyslipidemia
#5
T D Filippatos, M Florentin, M Georgoula, M S Elisaf
Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve their LDL-C target. However, many diabetic patients have increased residual CVD risk, which is mainly attributed to high triglycerides and low high-density lipoprotein (HDL-C) values. The addition of fenofibrate targets these variables and possibly reduces residual CVD risk, but a possible beneficial effect has been shown only in a pre-specified subgroup analysis in patients with high triglycerides and low HDL-C values...
December 2, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27868419/-research-progress-on-pharmacotherapy-of-calcific-aortic-valve-disease
#6
Miaomiao DU, Gaigai Ma, Yuping Shi
With the population aging and declining incidence of rheumatic heart disease, calcific aortic valve disease (CAVD) has become the most frequent valve disease and the common cause of aortic valve replacement. Patients with CAVD need to cope with a deteriorating quality of life and valve replacement is the only effective clinical option for the patients. Therefore, early pharmacotherapy is of great significance in prevention or slow-down of the progression of CAVD. For years CAVD was considered to be a passive wear and tear process of valves, but now it is recognized as an active and multi-factorial process...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27846466/increased-sortilin-and-its-independent-effect-on-circulating-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-in-statin-naive-patients-with-coronary-artery-disease
#7
Die Hu, Yang Yang, Dao-Quan Peng
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to play a crucial role in the metabolism of low density lipoprotein receptor (LDLR). Sortilin, encoded by the dyslipidemia-related gene SORT1, is also an important regulator of lipoprotein metabolism. Animal studies have shown the potential role of sortilin in regulating secretion of PCSK9. However, the data for the relationship between serum sortilin and circulating PCSK9 in CAD patients are scarce. METHODS: Eighty subjects were classified into a CAD group (n=43) and a non-CAD group (n=37) according to their clinical conditions and the results of coronary angiography (CAG)...
November 8, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27831597/pharmacological-management-of-dyslipidemia-in-high-and-very-high-cardiovascular-risk-patients
#8
V Pascual Fuster
Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia...
December 2016: Revista Española de Sanidad Penitenciaria
https://www.readbyqxmd.com/read/27829582/postprandial-hyperlipidemia-and-remnant-lipoproteins
#9
Daisaku Masuda, Shizuya Yamashita
Fasting hypertriglyceridemia is positively associated with the morbidity of coronary heart disease (CHD), and postprandial (non-fasting) hypertriglyceridemia is also correlated with the risk status for CHD, which is related to the increase in chylomicron (CM) remnant lipoproteins produced from the intestine. CM remnant particles, as well as oxidized low density lipoprotein (LDL) or very low density lipoprotein (VLDL) remnants, are highly atherogenic and act by enhancing systemic inflammation, platelet activation, coagulation, thrombus formation, and macrophage foam cell formation...
November 8, 2016: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/27826756/characteristics-associated-with-nonadherence-to-medications-for-hypertension-diabetes-and-dyslipidemia-among-breast-cancer-survivors
#10
Gregory S Calip, Joann G Elmore, Denise M Boudreau
OBJECTIVE: Comorbidity among breast cancer survivors is prevalent, and adherence to medication management of comorbidities may be important for both chronic disease and cancer-related outcomes. Our objective was to determine characteristics associated with nonadherence to common chronic medications among breast cancer survivors. METHODS: We conducted a retrospective cohort study of 4216 women in an integrated care system diagnosed with early-stage breast cancer between 1990 and 2008 and alive without recurrence or second primary breast cancer in the second-year following diagnosis...
November 8, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27819152/blood-pressure-and-lipid-target-adherence-in-korean-patients-receiving-angiotensin-ii-receptor-blockers-statin-regimens
#11
Hyun-Jin Kim, Eugene Kim, Kyoung-Bok Min, Jin-Young Min
OBJECTIVES: Hypertension and dyslipidemia are important cardiovascular risk factors. Simultaneously controlling blood pressure (BP) and lipid levels is effective in preventing cardiovascular events and premature death. This study investigated the association between adherence to angiotensin II receptor blocker (ARB)/statin regimens and BP or low density lipoprotein-cholesterol (LDL-C) target attainment in Korean patients with concomitant hypertension and dyslipidemia. METHODS: In this retrospective, multicenter study, we collected case report forms (CRFs) of hypertensive patients with concomitant dyslipidemia who were prescribed an ARB/statin regimen between 1 April 2014 and 31 March 2015 from 51 outpatient clinics...
December 2, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27792720/-effect-of-simvastatin-plus-inulin-in-comparison-with-simvastatin-plus-ezetimibe-on-the-treatment-of-mixed-dyslipidemia
#12
Esperanza Martínez-Abundis, Carmelita Barrera-Durán, Manuel González-Ortiz, Eduardo Hernández-Salazar
INTRODUCTION: Mixed dyslipidemia accelerates atherosclerosis and leads to cardiovascular disease and death. Non-soluble fibers such as inulin have been shown to have an effect on dyslipidemia. AIM: To assess the effect of the combination of simvastatin plus inulin in comparison with simvastatin plus ezetimibe in mixed dyslipidemia. MATERIAL AND METHODS: A randomized, double-blind, clinical trial with parallel control group was performed in 60 patients with mixed dyslipidemia, without drug treatment or failure to statins and lifestyle changes...
October 2016: Gaceta Médica de México
https://www.readbyqxmd.com/read/27773788/modulating-putative-endothelial-progenitor-cells-for-the-treatment-of-endothelial-dysfunction-and-cardiovascular-complications-in-diabetes
#13
REVIEW
Julien Wils, Julie Favre, Jérémy Bellien
Diabetes induces a decrease in the number and function of different pro-angiogenic cell types generically designated as putative endothelial progenitor cells (EPC), which encompasses cells from myeloid origin that act in a paracrine fashion to promote angiogenesis and putative "true" EPC that contribute to endothelial replacement. This not only compromises neovasculogenesis in ischemic tissues but also impairs, at an early stage, the reendotheliziation process at sites of injury, contributing to the development of endothelial dysfunction and cardiovascular complications...
October 20, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27773403/statin-therapy-lipid-lowering-therapy-among-indian-adults-with-first-acute-coronary-event-the-dyslipidemia-residual-and-mixed-abnormalities-in-spite-of-statin-therapy-remains-study
#14
Salgaonkar V Jaywant, A K Singh, Mundkur S Prabhu, R Ranjan
OBJECTIVE: The primary objective was to evaluate the effect of statin therapy/lipid lowering therapy (LLT) on lipid profile, in adults presenting with first acute coronary event. METHODS AND MATERIAL: A multicentre, observational, prospective cohort study of lipid profiles pre- and post-statin therapy/LLT, among adult patients with confirmed diagnosis of first acute coronary event. The primary outcome measures were low-density lipoprotein cholesterol (LDL-C) in mg/dl, high-density lipoprotein cholesterol (HDL-C) in mg/dl and triglycerides (TG) in mg/dl at baseline and end of study (EOS, 12 weeks [mean: 13...
September 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27773395/differential-residual-dyslipidemia-cardiovascular-risk-after-statin-treatment-between-asian-indians-and-western-whites-call-for-action
#15
EDITORIAL
Vasilios Gabriel Athyros, Michael Doumas, Asterios Karagiannis
No abstract text is available yet for this article.
September 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27770320/-ldl-cholesterol-and-cardiovascular-events-the-lower-the-better
#16
Raimund Weitgasser, Michaela Ratzinger, Margit Hemetsberger, Peter Siostrzonek
For over 30 years, intensive research efforts investigated the role of LDL cholesterol in the pathogenesis of cardiovascular disease. In various settings, large statin trials showed an association between LDL cholesterol levels and cardiovascular event rates. This association is often referred to as the 'LDL cholesterol hypothesis'. More recent trials on agents with totally different modes of action confirmed this association and indicated a causal relationship between lower LDL cholesterol levels and improved cardiovascular outcomes...
October 21, 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27765794/inhibition-of-aberrant-microrna-133a-expression-in-endothelial-cells-by-statin-prevents-endothelial-dysfunction-by-targeting-gtp-cyclohydrolase-1-in-vivo
#17
Peng Li, Ya-Ling Yin, Tao Guo, Xue-Ying Sun, Hui Ma, Mo-Li Zhu, Fan-Rong Zhao, Ping Xu, Yuan Chen, Guang-Rui Wan, Fan Jiang, Qi-Sheng Peng, Chao Liu, Li-Ying Liu, Shuang-Xi Wang
BACKGROUND: -GTP cyclohydrolase 1 (GCH1) deficiency is critical for endothelial nitric oxide synthase (eNOS) uncoupling in endothelial dysfunction. MicroRNAs (miR) are a class of regulatory RNAs that negatively regulate gene expression. We investigated whether statins prevent endothelial dysfunction via miR-dependent GCH1 upregulation. METHODS: -Endothelial function was assessed by measuring acetylcholine- induced vasorelaxation in the organ chamber. MiR-133a expression was assessed by RT-qPCR and fluorescence in situ hybridization...
October 20, 2016: Circulation
https://www.readbyqxmd.com/read/27759359/statin-induced-rhabdomyolysis
#18
Sachinkumar N Ambapkar, Naresh Shetty, Arpita Dwivedy
Rhabdomyolysis is syndrome characterized by muscle necrosis which causes the release of myoglobin into the bloodstream. The manifestations of this syndrome range from asymptomatic elevation of muscle enzymes to life-threatening cases associated with extremely high enzyme levels, electrolyte imbalance and acute renal failure. Symptoms of rhabdomyolysis include dark urine, muscle weakness and fatigue. Statins are the most commonly used drugs for prevention and management of dyslipidemia. We present an interesting case report on statin induced rhabdomyolysis with renal failure...
July 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27754291/br-08-3-management-of-dyslipidemia-in-hypertension
#19
V V Muthusamy
Cardiovascular disease burden is increasing all over the world. The diagnosis of hypertension is considered when a person has persistently elevated BP (Systolic BP more than 140 mmHg and/or Diastolic BP more than 90 mmHg). Dyslipidemia denotes abnormal levels of lipids in the blood (Total Cholesterol >200 mg%, Low density lipoprotein (LDL) >100 mg%, Triglycerides (TGL) >150 mg% and High density lipoprotein (HDL) <40 mg in men and < 50 mg in women. Hypertension and Dyslipidemia constitute the important components of metabolic syndrome as per the definition of NCEP Guidelines-Adult Treatment Panel III (ATP III)...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27753819/ssa-06-4-risk-factors-and-compliance-at-hypertensives-west-siberia-residents
#20
Davyd Yakhontov
OBJECTIVE: To study the risk factors (RF) prevalence and compliance in hypertension (Ht) associated with coronary artery diseases (CAD) pts - West Siberia residents. MATERIAL AND METHOD: 151 pts with Ht grade 1-3 and stable angina 54,8 ± 0,7 years old divided in 3 groups. The 1 group included 43 Ht pts with uncomplicated angina and intact coronary arteries, the 2 group - 47 Ht pts with angina and percutaneous coronary intervention last 1-3 years, the 3 group - 61 Ht pts with myocardial infarction (MI) or stroke last 1-3 years...
September 2016: Journal of Hypertension
keyword
keyword
118412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"